edgewise therapeutics is a biotechnology company focused on developing novel therapies for diseases involving skeletal muscle. the company is headquartered in boulder, co and received its series a financing from orbimed.
Company profile
Ticker
EWTX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
821725586
EWTX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
15 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22 Feb 24
424B5
Prospectus supplement for primary offering
19 Jan 24
8-K
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
19 Jan 24
8-K
Results of Operations and Financial Condition
19 Jan 24
S-3MEF
Registration of additional securities for an S-3
19 Jan 24
424B3
Prospectus supplement
19 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
Latest ownership filings
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
4
JOHN R MOORE
9 Feb 24
4
Behrad Derakhshan
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BlackRock Inc.
7 Feb 24
144
Notice of proposed sale of securities
7 Feb 24
144
Notice of proposed sale of securities
7 Feb 24
SC 13G
BlackRock Inc.
2 Feb 24
SC 13G/A
Flynn James E
1 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.96 mm | 32.96 mm | 32.96 mm | 32.96 mm | 32.96 mm | 32.96 mm |
Cash burn (monthly) | (no burn) | 6.40 mm | 9.82 mm | 8.55 mm | 7.35 mm | 6.41 mm |
Cash used (since last report) | n/a | 42.77 mm | 65.62 mm | 57.13 mm | 49.14 mm | 42.87 mm |
Cash remaining | n/a | -9.81 mm | -32.66 mm | -24.18 mm | -16.19 mm | -9.92 mm |
Runway (months of cash) | n/a | -1.5 | -3.3 | -2.8 | -2.2 | -1.5 |
Institutional ownership, Q2 2023
82.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 95 |
Opened positions | 11 |
Closed positions | 3 |
Increased positions | 40 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 535.77 bn |
Total shares | 76.36 mm |
Total puts | 2.00 k |
Total calls | 16.00 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 14.57 mm | $112.90 bn |
FMR | 7.36 mm | $57.02 bn |
Novo Holdings A/S | 6.07 mm | $47.06 bn |
Viking Global Investors | 5.94 mm | $46.06 bn |
Deerfield Management | 3.93 mm | $30.48 bn |
Flynn James E | 3.93 mm | $0.00 |
EcoR1 Capital | 3.49 mm | $27.07 bn |
BLK Blackrock | 3.13 mm | $24.29 bn |
Cormorant Asset Management | 2.95 mm | $22.84 bn |
Cormorant Global Healthcare Master Fund | 2.95 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Feb 24 | Behrad Derakhshan | Common Stock | Sell | Dispose S | No | No | 20.0436 | 4,800 | 96.21 k | 7,020 |
9 Feb 24 | Behrad Derakhshan | Common Stock | Option exercise | Acquire M | No | No | 1.93 | 4,800 | 9.26 k | 11,820 |
9 Feb 24 | Behrad Derakhshan | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.93 | 4,800 | 9.26 k | 145,017 |
9 Feb 24 | John R Moore | Common Stock | Sell | Dispose S | No | No | 20.0096 | 8,029 | 160.66 k | 0 |
9 Feb 24 | John R Moore | Common Stock | Option exercise | Acquire M | No | No | 1.93 | 8,029 | 15.50 k | 8,029 |
9 Feb 24 | John R Moore | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.93 | 8,029 | 15.50 k | 93,162 |
8 Feb 24 | Behrad Derakhshan | Common Stock | Sell | Dispose S | No | No | 20.0106 | 4,600 | 92.05 k | 7,020 |
8 Feb 24 | Behrad Derakhshan | Common Stock | Option exercise | Acquire M | No | No | 1.93 | 4,600 | 8.88 k | 11,620 |
8 Feb 24 | Behrad Derakhshan | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.93 | 4,600 | 8.88 k | 149,817 |
8 Feb 24 | John R Moore | Common Stock | Sell | Dispose S | No | No | 20.0065 | 3,813 | 76.28 k | 0 |
News
Truist Securities Maintains Buy on Edgewise Therapeutics, Maintains $25 Price Target
17 Apr 24
Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $26 Price Target
16 Apr 24
Edgewise Therapeutics Reports Two-Year Topline Results From ARCH Open Label Trial Of Sevasemten In Adults With Becker Muscular Dystrophy; Sevasemten Was Well-Tolerated
15 Apr 24
RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $28 Price Target
12 Mar 24
Piper Sandler Initiates Coverage On Edgewise Therapeutics with Overweight Rating, Announces Price Target of $48
7 Mar 24
Press releases
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
15 Apr 24
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
28 Mar 24
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
27 Mar 24
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
13 Feb 24